ArticleNPJ breast cancer2022

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.

Adrienne G Waks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.